Prescription medicine
Insulin aspart Brand names: Novolog, Fiasp, Kirsty, Garzulys, Merilog; first approved as Fiasp Penfill
Insulin aspart (Novolog) is a prescription medicine with an FDA approval on record since 2017. No generic is listed; pharmacies paid $6.95 per mL (Insulin aspart 100 unit/mL vial) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the insulin aspart FDA label on DailyMed (effective June 21, 2023, Novo Nordisk); the BLA 208751 record on Drugs@FDA; every insulin aspart label on DailyMed.
Highlights of the record
FDA label of June 21, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Forms and strengths
Injection (solution); injection (suspension).
On the market
- Earliest approval on file
- September 29, 2017 Fiasp Penfill, Novo; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 8 of which 0 under generic applications, 8 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $6.95 per mL Insulin aspart 100 unit/mL vial
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 5 since 2021 5 Class I among all firms' recalls; latest March 22, 2021
- FAERS reports
- 63,003 through July 30, 2026
What is insulin aspart used for?
From the label: indications and usageFIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
FIASP is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ).
Conditions named in the indications of insulin aspart's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Insulin Analog.
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
What does the patient leaflet for insulin aspart say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What should I avoid while taking FIASP?While taking FIASP do not: • Drive or operate heavy machinery until you know how FIASP affects you. • Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.
From the patient leaflet: How should I store FIASP?Do not freeze FIASP. Do not use FIASP if it has been frozen. • Keep FIASP away from excessive heat or light. All unopened vials: • Store unopened FIASP vials in the refrigerator at 36 ° F to 46 ° F (2 ° C to 8 ° C) or at room temperature below 86 ° F (30 ° C). • If unopened vials have been stored in the refrigerator, vials may be used until the expiration date printed on the label. • If unopened vials have been stored at room temperature, vials should be thrown away after 28 days. After vials have been opened: • Opened FIASP vials can be stored in the refrigerator at 36 ° F to 46 ° F (2 ° C to 8 ° C) or at room temperature below 86 ° F (30 ° C). • Throw away all opened FIASP vials after 28 days (including 6 days pump in-use time), even if they still have insulin left in them.
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
Is there a generic for insulin aspart (Novolog)?
No generic insulin aspart is approved (Drugs@FDA, October 8, 2026).
- 2017 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for insulin aspart (Novolog)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $6.95 per mL (Insulin aspart 100 unit/mL vial), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Insulin aspart protamine-insulin aspart mix 70-30 vial (generic)
- Merilog 100 unit/mL vial (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Insulin aspart 100 unit/mL vial | Generic | $6.95 per mL | n/a | no change |
| Insulin aspart flexpen 100 unit/mL pen | Generic | $8.96 per mL | n/a | no change |
| Insulin aspart penfill 100 unit/mL cartridge | Generic | $8.57 per mL | n/a | -0.2% |
| Insulin aspart protamine-insulin aspart mix 70-30 flexpen | Generic | $8.93 per mL | n/a | -0.3% |
| Insulin aspart protamine-insulin aspart mix 70-30 vial | Generic | $6.95 per mL | n/a | no change |
| Fiasp 100 unit/mL flextouch | Brand | $8.91 per mL | n/a | -75% |
| Fiasp 100 unit/mL vial | Brand | $6.92 per mL | n/a | -75% |
| Fiasp penfill 100 unit/mL cart | Brand | $8.55 per mL | n/a | -75% |
| Fiasp pumpcart 100 unit/mL | Brand | $8.57 per mL | n/a | -75% |
| Merilog 100 unit/mL vial | Brand | $6.82 per mL | n/a | n/a |
| Merilog solostar 100 unit/mL | Brand | $8.72 per mL | n/a | n/a |
| Novolog 100 unit/mL flexpen | Brand | $8.94 per mL | n/a | no change |
| Novolog 100 unit/mL vial | Brand | $6.94 per mL | n/a | -0.1% |
| Novolog mix 70-30 flexpen | Brand | $8.94 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has insulin aspart been recalled?
The FDA's Enforcement Report lists 5 recalls naming insulin aspart since 2021: 5 Class I (the most serious), 0 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 22, 2021 | Class I | Novo Nordisk Inc | Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the insulin aspart label say about other medicines?
The insulin aspart label names 18 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Albuterol | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose increases and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs. |
| Clonidine | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Clozapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Danazol | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Disopyramide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Epinephrine | drug interactions | … (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose increases and increased frequency of glucose monitoring may be required when FIASP is co-administered with these drugs. |
| Fluoxetine | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Glucagon | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Isoniazid | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Lithium | drug interactions | Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. |
| Niacin | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Octreotide | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Olanzapine | drug interactions | Drugs That May Decrease the Blood Glucose Lowering Effect of FIASP Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors … |
| Pentoxifylline | drug interactions | Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
Every other medicine the insulin aspart label names
| Medicine named | Section | What the label says |
|---|---|---|
| Pramlintide | drug interactions | … fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. … |
| Protamine | contraindications | CONTRAINDICATIONS Insulin Aspart Protamine and Insulin Aspart Mix 70/30 is contraindicated: |
| Somatropin | drug interactions | … progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. … |
| Terbutaline | drug interactions | … somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose increases and increased frequency of glucose monitoring may be required when … |
Source: FDA drug label (Fiasp), Novo Nordisk, effective June 21, 2023 (SPL set 834e7efc-393f-4c55-9125-628562a8a5cf), via openFDA; the full label on DailyMed
What do FAERS reports show for insulin aspart?
The FDA Adverse Event Reporting System holds 63,003 reports that list insulin aspart among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 4,460 are coded as a death and 20,796 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
How does insulin aspart compare with medicines for the same use?
2 side-by-side pages set insulin aspart beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to insulin aspart
- medicines labeled for the same conditions
- Other insulin analogs
- the pharmacologic class, with prices and generics
- Insulin aspart side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other